TCT 2014 Late-breaking Trials and First Report Investigations

Transcatheter Cardiovascular Therapeutics (TCT) has announced the late-breaking trial presentations at TCT 2014, Sept. 13-17.

Late-breaking clinical trials are typically first-time international or U.S. presentations of the primary endpoint or important secondary endpoint results of prospective, randomized clinical trials or presentations of large-scale, impactful single-center or multicenter registries. A first-report investigation is a smaller randomized trial, novel science, or early-human investigation.

All presentations will take place in the Main Arena area in the ballroom on level 3.

Saturday, Sept. 12 — Main Arena I

• 11 a.m.— PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis. Presented by Samir R. Kapadia.

• 11:24 a.m. — U.S. CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis. Presented by Matthew R. Reynolds.

• 11:42 a.m. — CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Presented by Axel Linke.

• Noon — The CoreValve US Pivotal Trial: Two-Year Results with a Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis. Presented by Steven J. Yakubov.

• 12:15 p.m. — ISAR-CLOSURE: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access. Presented by Stefanie Schulz.

Sunday, Sept. 14 — Main Arena II

• 11 a.m. — ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease. Presented by Patrick W. Serruys.

• 11:24 a.m. — DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions. Presented by Shao Liang Chen.

• 11:42 a.m. — RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents. Presented by Fernando Alfonso.

Noon — IVUS-CTO: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions. Presented by Yang-Soo Jang.

• 12:15 p.m. — OCT STEMI: A Prospective, Randomized Trial of Optical Coherence Tomography Guidance During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Presented by Pavel Cervinka.

Monday, Sept. 15 — Main Arena III

• 11:10 a.m. — BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention. Presented by Yaling Han.

• 11:30 a.m. — ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation. Presented by Nikolaus Sarafoff.

• 11:48 a.m. — SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation. Presented by

Antonio Colombo.

• 12:06 p.m. — TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. . Presented by Tracy Y. Wang.

• 12:21 p.m. — VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Presented by Gregg W. Stone.

Tuesday, Sept. 16 — Main Arena IV

• 11 a.m. — PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura. Presented by David Hildick-Smith.

• 11:24a.m. — Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Mild Refractory Hypertension. . Presented by Steffen Desch

• 11:42 a.m. — EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis. Presented by Eric J. Dippel.

Noon — I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease. Presented by Bo Xu.

• 12:15 p.m. — EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease. Presented by Stephane Cook.